Characteristics of the Vergence Responses of Binocularly Normal Subjects After a Vision Therapy Protocol

Last updated: January 25, 2022
Sponsor: Universitat Politècnica de Catalunya
Overall Status: Active - Recruiting

Phase

N/A

Condition

Eye Disorders/infections

Tic Disorders

Dystonias

Treatment

N/A

Clinical Study ID

NCT05208658
Vergence VT Protocol
  • Ages 20-30
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A vision therapy protocol for vergence ability is mentioned. The purpose of this study is to evaluate objectively the change in the vergence responses of binocular and accommodative normal subjects after performing a classic vision therapy protocol. This study is an interventional, cross-over, and randomized study.

Eligibility Criteria

Inclusion

Normal binocular and accommodative subjects will participate in the study. All subjectshave to fulfill the inclusion criteria. All evaluations will consist of the followingobjective and subjective optometric tests, which will be executed for all participants.

  1. Monocular and binocular VA at near and distance with their habitual correction
  2. Refractive error measured with the Grand Seiko WAM-5500 Autorefractor
  3. Cover Test at near (40 cm)
  4. Near Point of Accommodation
  5. Near Point of Convergence
  6. Vergence Facility Test at near (40 cm)
  7. Monocular and binocular Accommodation Facility Test at near (40 cm)
  8. Negative and Positive Relative Accommodation Test (ARN and ARP)
  9. Random Dot 2 Stereo acuity Test
  10. CISS questionnaire
  11. Fusional Vergence Amplitude using both subjective and objective methods

Exclusion

Exclusion Criteria:

  • having eye surgery
  • having an eye pathology
  • having a binocular or an accommodative disorder
  • using orto-K lenses

Study Design

Total Participants: 34
Study Start date:
September 02, 2021
Estimated Completion Date:
March 29, 2022

Study Description

After the first evaluation, subjects will be classified in the Experimental Group (EG) or Control Group (CG) randomly. There will be 18 subjects in each group. A classic vision therapy protocol for fusional vergence will be performed in the EG and the CG will be doing a placebo therapy, based on studies done before.

The EG will do weekly office-based therapy of 45 minutes during 12 weeks and the CG will do weekly office-based placebo therapy of 15 minutes during 12 weeks. This placebo therapy will consist of smooth-pursuit and discrimination exercises that do not influence vergence response. The office-based done by the EG consists of a vergence therapy and its protocol will follow Scheiman's indications protocol. This vision therapy will train both positive and negative fusional vergence amplitudes in the same proportion.

A pre-evaluation, a during evaluation, and a post-evaluation will be done at weeks 1, 6, and 12 respectively to all subjects. After the post-evaluation week, the CG will do 12 weeks more of office-based therapy but, this group will do the same conventional vergence protocol as EG. The CG will be evaluated at week 18, and finally, at week 24.

During the evaluations, the vergence eye movements will be measured during the positive and negative fusional vergence tests. The break and the recovery points will be evaluated to all the subjects with three different methods performed in a randomized order: (1) objective computer-based test in the haploscopic system, (2) prism bar, and (3) phoropter rotary prisms. All these tests will be performed at 40 cm with a classic central visual target.

This study aims to evaluate objectively the change in the vergence responses of binocular and accommodative normal subjects after performing a classic vision therapy protocol.

Connect with a study center

  • Cristina Rovira-Gay

    Barcelona, 08222
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.